PROPHASE LABS INC. overview

ProPhase Labs CEO Ted Karkus explains how the spike in COVID cases has impacted his company, noting that he is 'hiring like ......

DOYLESTOWN, Pa., March 16, 2018 (GLOBE NEWSWIRE) -- ProPhase Labs (NASDAQ:PRPH) announced today that financial results for the year ended December 31, 2017, will be released before the market opens on Wednesday, March 21, 2018. A conference call will be held on Wednesday March 21, at 11:00 a.m. EST. ProPhase Labs Chairman and CEO, Ted Karkus will provide a company overview including a review of activities and year end results. There will be a question and answer session following initial...

DOYLESTOWN, Pa., Feb. 20, 2018 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ:PRPH) (www.ProPhaseLabs.com), a vertically integrated and diversified branding, marketing and technology company with deep experience in over-the-counter dietary supplements and remedies (“ProPhase” or “Company”), announced today that its Board of Directors has approved a new employment agreement with Ted Karkus, the Company’s Chief Executive Officer, which will become effective February 23, 2018. Pursuant...

DOYLESTOWN, Pa., Nov. 20, 2017 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ:PRPH) (www.ProPhaseLabs.com), a diversified natural health medical science company (the “Company” or “ProPhase”), today announced that it has commenced a tender offer to purchase up to 1.7 million shares of its common stock at a price of $2.30 per share. The number of shares proposed to be purchased in the tender offer represents approximately 13.7% of the approximately 12.4 million shares of ProPhase’s...

DOYLESTOWN, Pennsylvania, Nov. 13, 2017 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ:PRPH) (www.ProPhaseLabs.com) today reported its financial results for the three months and nine months ended September 30, 2017. As previously announced, effective March 29, 2017 and with the approval of the Company’s stockholders, the Company completed the sale of assets comprised principally of the intellectual property rights and other assets relating to the Cold-EEZE ® brand and product line...

DOYLESTOWN, Pa., Nov. 10, 2017 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ:PRPH) (www.ProPhaseLabs.com), a diversified natural health medical science company (the “Company” or “ProPhase”), today announced that it intends to commence a tender offer to purchase up to 1,700,000 shares of its common stock at a price per share of $2.30 per share. The Company anticipates that the tender offer will be launched on or before November 20, 2017 and will remain open for at least 20 business days...

DOYLESTOWN, Pa., Sept. 29, 2017 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ:PRPH) (www.ProPhaseLabs.com), a diversified natural health medical science company (“ProPhase”), announced today the final results of its tender offer to purchase up to 4,000,000 shares of its common stock at a price of $2.30 per share, which expired at 5:00 p.m., New York City time, on September 25, 2017. ProPhase has accepted for purchase 4,323,335 shares of its Common Stock, including all “odd lots”...

DOYLESTOWN, Pa., Sept. 26, 2017 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ:PRPH) ( www.ProPhaseLabs.com ), a diversified natural health medical science company (“ProPhase”), announced today the preliminary results of its tender offer to purchase up to 4,000,000 shares of its common stock at a price of $2.30 per share, which expired at 5:00 p.m., New York City time, on September 25, 2017. Based on the preliminary count by American Stock Transfer & Trust Company, the Depositary for the...